Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US
Category: News
Results suggest bispecific antibody combination could improve outcomes
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen
EMHA calls for its inclusion in EU neurological health strategy
Three-year data highlights inflammation control in psoriatic arthritis
Rheumatology studies show promising results for Sjogren’s disease
Biotech firm to collaborate with NHS on early detection study
Therapy indicated for children aged 3 to 14 at treatment initiation
New funding supports development of diagnostic platform